Ribend 25 & 100 25 mg, 100 mg Concentrate For Solution For Infusion
PDF Leaflet Revision Date: 10 February 2023
Clinical Summary
Quick overview from the medicine insert
Indication
First-line treatment for specific leukemias and lymphomas.
Dosage (summary)
IV infusion over 30-60 mins; varies by condition.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- CYP1A2 inhibitors
- Myelosuppressive agents
- Ciclosporin
- Tacrolimus
Contraindications
- Hypersensitivity
- Severe hepatic impairment
- Severe bone marrow suppression
- Infections
- Live vaccinations
Common side effects
- Leucopenia
- Thrombocytopenia
- Nausea
- Vomiting
- Fever
Counselling Points
- Avoid pregnancy during treatment
- Monitor for signs of infection
- Report severe skin reactions
- Discuss sperm conservation options
Serious warnings
- Myelosuppression
- Infection risk
- Skin reactions
- QT prolongation
- Tumor lysis syndrome
Important Disclaimer
The Ribend 25 & 100 25 mg, 100 mg Concentrate For Solution For Infusion professional information leaflet below is the property of Innovata Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
